South San Francisco Newswire

Comprehensive Real-Time News Feed for South San Francisco, CA.

Results 1 - 9 of 9 for "" in South San Francisco, CA

  1. Cytokinetics Provides Development Program Update for Omecamtiv MecarbilRead the original story

    Monday Oct 27 |

    Over 275 Patients Enrolled in COSMIC-HF; Data Monitoring Committee Recommends Continuation with No Changes to the Protocol Phase I Pharmacokinetic and Safety Study Comparing Japanese and Caucasian Volunteers Completed SOUTH SAN FRANCISCO, CA, October 27, 2014 - Cytokinetics, Incorporated provided an update today relating to omecamtiv mecarbil, the company's lead drug candidate from its cardiac muscle contractility program. The company announced that COSMIC-HF has enrolled over 275 patients towards the objective of 450 patients in the ongoing expansion phase of the trial.


  2. Cytokinetics Provides Development Program Update for TirasemtivRead the original story

    Monday Oct 20 |

    Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-ALS Support Progression to Phase III Company Believes Effects on Slow Vital Capacity Could Support Registration Path For Tirasemtiv SOUTH SAN FRANCISCO, CA, October 20, 2014 - Cytokinetics, Incorporated provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful.


  3. Cytokinetics to Announce Third Quarter Results on October 30, 2014Read the original story

    Thursday Oct 16 |

    South San Francisco, CA., October 16, 2014, - Cytokinetics, Incorporated announced today that it is scheduled to report third quarter results on Thursday, October 30, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.


  4. Cytokinetics Announces Development Program Update for CK-2127107Read the original story

    Monday Oct 13 |

    Company Completes Program of Five Phase I Clinical Trials Pursuant to Agreed Development Plan with Astellas South San Francisco, CA, October 13, 2014 - Cytokinetics, Incorporated announced the completion of five Phase I clinical trials evaluating CK- 2127107 in healthy volunteers, and certain other Phase II readiness activities, all in connection with the agreed development plan under the collaboration between Cytokinetics and Astellas Pharma Inc. . The Phase I clinical trials demonstrated that CK-2127107 appeared safe and well- tolerated in healthy volunteers and that exposures generally increased across dose ranges studied.


  5. New Report Available: Onyx Pharmaceuticals, Inc. (ONXX) - Strategic SWOT Analysis ReviewRead the original story

    Sep 29, 2014 |

    The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.


  6. New Market Report: Poniard Pharmaceuticals, Inc. (PARD) -...Read the original story

    Sep 19, 2014 |

    The company focused on developing picoplatin product, which is a new generation platinum based cancer therapy. Picoplatin is designed to overcome platinum resistance in the treatment of solid tumors.


  7. Recent Study: Fluidigm Corporation (FLDM) - Medical Equipment - Deals and Alliances ProfileRead the original story

    Sep 18, 2014 |

    The company manufactures and markets microfluidic-based chips and instrumentation for biological research. Its products and systems include biomark HD system, C1 system, EP1 system, access array system, chips and kits, DELTagene assays, SNPtype assays, target-specific primers and software.


  8. Portola Pharmaceuticals, Inc. (PTLA) - Pharmaceuticals & Healthcare - ...Read the original story

    Sep 12, 2014 |

    It undertakes the discovery and development of innovative therapeutics for the treatment of cardiovascular, inflammation, and oncology indications. The company's product portfolio includes Betrixaban, Andexanet Alfa , PRT2607, and PRT2070.


  9. Recent Study: Fluidigm Corporation (FLDM) - Pharmaceuticals &...Read the original story

    Aug 19, 2014 |

    The company manufactures and markets microfluidic-based chips and instrumentation for biological research.


South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.